Aktis Oncology rallies $72m Series A

Aktis Oncology, a biotechnology company focused on treating solid tumor cancers, has secured $72 million in Series A financing.

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.

Share this